The Effect of Dynamic, In Vivo-like Oxaliplatin on HCT116 Spheroids in a Cancer-on-Chip Model Is Representative of the Response in Xenografts
Authors:
- Job KomenJKJob Komen
- Sanne M. van NeervenSNSanne M. van Neerven
- Elsbeth G. B. M. BossinkEBElsbeth G. B. M. Bossink
- Nina E. de GrootNGNina E. de Groot
- Lisanne E. NijmanLNLisanne E. Nijman
- Albert van Den BergAlbert van Den Berg
- Louis VermeulenLVLouis Vermeulen
- Andries D. van der MeerAMAndries D. van der Meer
Open Access
- 6 May 2022
- journal article
- research article
- Published by MDPI AG in Micromachines
- Vol. 13 (5) , 739
Abstract
The cancer xenograft model in which human cancer cells are implanted in a mouse is one of the most used preclinical models to test the efficacy of novel cancer drugs. However, the model is imperfect; animal models are ethically burdened, and the imperfect efficacy predictions contribute to high clinical attrition of novel drugs. If microfluidic cancer-on-chip models could recapitulate key elements of the xenograft model, then these models could substitute the xenograft model and subsequently surpass the xenograft model by reducing variation, increasing sensitivity and scale, and adding human factors. Here, we exposed HCT116 colorectal cancer spheroids to dynamic, in vivo-like, concentrations of oxaliplatin, including a 5 day drug-free period, on-chip. Growth inhibition on-chip was comparable to existing xenograft studies. Furthermore, immunohistochemistry showed a similar response in proliferation and apoptosis markers. While small volume changes in xenografts are hard to detect, in the chip-system, we could observe a temporary growth delay. Lastly, histopathology and a pharmacodynamic model showed that the cancer spheroid-on-chip was representative of the proliferating outer part of a HCT116 xenograft, thereby capturing the major driver of the drug response of the xenograft. Hence, the cancer-on-chip model recapitulated the response of HCT116 xenografts to oxaliplatin and provided additional drug efficacy information.Keywords
Funding Information
- Nederlandse Organisatie voor Wetenschappelijk Onderzoek (024.003.001)
This publication has 55 references indexed in Scilit:
- Causes, consequences, and remedies for growth-induced solid stress in murine and human tumorsProceedings of the National Academy of Sciences, 2012
- High drug attrition rates—where are we going wrong?Nature Reviews Clinical Oncology, 2011
- Role of Organic Cation Transporter 1, OCT1 in the Pharmacokinetics and Toxicity of cis-Diammine(pyridine)chloroplatinum(II) and Oxaliplatin in MicePharmaceutical Research, 2010
- Oncogenic KRAS sensitises colorectal tumour cells to chemotherapy by p53-dependent induction of NoxaBritish Journal of Cancer, 2010
- From the cellular perspective: exploring differences in the cellular baseline in macroscale and microfluidic culturesIntegrative Biology, 2009
- Transport kinetics of four- and six-coordinate platinum compounds in the multicell layer tumour modelBritish Journal of Cancer, 2007
- Continuous perfusion microfluidic cell culture array for high‐throughput cell‐based assaysBiotechnology and Bioengineering, 2004
- Microregional Effects of Gemcitabine in HCT-116 XenograftsCancer Research, 2004
- Comparative pharmacokinetics of oxaliplatin (L‐OHP) and carboplatin (CBDCA) in mice with reference to circadian dosing timeBiopharmaceutics & Drug Disposition, 1994
- A pharmacodynamic model for cell-cycle-specific chemotherapeutic agentsJournal of Pharmacokinetics and Biopharmaceutics, 1973